Literature DB >> 7949181

Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes.

F A Asimakopoulos1, N J White, E Nacheva, A R Green.   

Abstract

Acquired deletions of the long arm of chromosome 20 are found in several hematologic conditions and particularly in the myeloproliferative disorders and myelodysplastic syndromes. The spectrum of diseases associated with 20q deletions suggests that such deletions may mark the site of a tumor suppressor gene that contributes to the regulation of normal multipotent hematopoietic progenitors. We present here the first detailed molecular analysis of 20q deletions associated with myeloid disorders. Thirty-four microsatellite primer pairs corresponding to loci on 20q have been used to study DNA samples from two cell lines and from highly purified peripheral blood granulocytes obtained from seven patients. In addition, Southern analysis of cell line DNA has been performed using 19 DNA probes that map to 20q. Three conclusions can be drawn from our results. Firstly, molecular heterogeneity of both centromeric and telomeric breakpoints was demonstrated, thus supporting the existence of a tumor suppressor gene on 20q. In addition many of the breakpoints have been mapped to small genetic intervals. Secondly, our results define a commonly deleted region of 16-21 cM which contains ADA, PLC1, TOP1, SEMG1, and PPGB. Several candidate tumor suppressor genes lie outside the common deleted region including SRC, HCK, p107, PTPN1, and CEBP beta. Thirdly, the data allow integration of genetic and physical maps and have refined the map positions of multiple genes. These results will facilitate attempts to identify candidate hematopoietic tumor suppressor genes on 20q.

Entities:  

Mesh:

Year:  1994        PMID: 7949181

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Microarray CGH analysis of hematological patients with del(20q).

Authors:  Chunxiao Wu; Jinlan Pan; Huiying Qiu; Yongquan Xue; Suning Chen; Yafang Wu; Jun zhang; Shuxiao Bai; Yong Wang; Juan Shen; Yanlei Gong
Journal:  Int J Hematol       Date:  2015-10-06       Impact factor: 2.490

Review 2.  Myeloproliferative disorders.

Authors:  Ross L Levine; D Gary Gilliland
Journal:  Blood       Date:  2008-09-15       Impact factor: 22.113

3.  Semenogelin I expression in myeloma cells can be upregulated pharmacologically.

Authors:  Yana Zhang; Zhiqing Wang; Jian Zhang; Benjamin Farmer; Seah H Lim
Journal:  Leuk Res       Date:  2008-05-12       Impact factor: 3.156

4.  Clinical Correlates of Autosomal Chromosomal Abnormalities in an Electronic Medical Record-Linked Genome-Wide Association Study: A Case Series.

Authors:  Hayan Jouni; Khader Shameer; Yan W Asmann; Ribhi Hazin; Mariza de Andrade; Iftikhar J Kullo
Journal:  J Investig Med       Date:  2013-10       Impact factor: 2.895

5.  Gain of chromosome 20 is a frequent aberration in liver metastasis of colorectal cancers.

Authors:  A Nanashima; H Yamaguchi; T Yasutake; T Sawai; H Kusano; Y Tagawa; T Nakagoe; H Ayabe
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

6.  p107 in the public eye: an Rb understudy and more.

Authors:  Stacey E Wirt; Julien Sage
Journal:  Cell Div       Date:  2010-04-02       Impact factor: 5.130

7.  Pseudo-Gaucher cell proliferation associated with myelodysplastic syndrome.

Authors:  Takeshi Saito; Noriko Usui; Osamu Asai; Nobuaki Dobashi; Hiroyuki Ida; Makio Kawakami; Shingo Yano; Hiroshi Osawa; Yutaka Takei; Shinobu Takahara; Yoji Ogasawara; Yuko Yamaguchi; Jiro Minami; Keisuke Aiba
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

8.  Ectopic expression of C/EBPalpha and ID1 is sufficient to restore defective neutrophil development in low-risk myelodysplasia.

Authors:  Christian R Geest; Miranda Buitenhuis; Edo Vellenga; Paul J Coffer
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

9.  Identification of protamine 1 as a novel cancer-testis antigen in early chronic lymphocytic leukaemia.

Authors:  Farouk Meklat; Yana Zhang; Masum Shahriar; Sharif U Ahmed; Wei Li; Nikolaos Voukkalis; Zhiqing Wang; Jian Zhang; Suhkrob Mastulov; Andrew Jewell; Thomas Giannakouros; Seah H Lim
Journal:  Br J Haematol       Date:  2008-11-22       Impact factor: 6.998

10.  Core promoter sequence of SEMG I spans between the two putative GATA-1 binding domains and is responsive to IL-4 and IL-6 in myeloma cells.

Authors:  Yana Zhang; Zhiqing Wang; Jian Zhang; Seah H Lim
Journal:  Leuk Res       Date:  2008-07-07       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.